Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications.

Tan A, Dang Y, Chen G, Mo Z.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):13405-10. eCollection 2015.

2.

Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: evidence from meta-analysis.

Tong J, Ao R, Wang Y, Chang B, Wang BY.

Int J Clin Exp Med. 2014 Sep 15;7(9):3096-105. eCollection 2014.

3.

Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.

Wang W, Zhang M, Sun W, Yang S, Su Y, Zhang H, Liu C, Li X, Lin L, Kim S, Okunieff P, Zhang Z, Zhang L.

PLoS One. 2013 Oct 25;8(10):e74272. doi: 10.1371/journal.pone.0074272. eCollection 2013.

4.
5.

Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

Ge Z, Sanders AJ, Ye L, Jiang WG.

Exp Ther Med. 2011 Mar;2(2):167-172. Epub 2011 Jan 20.

6.
7.

Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability.

Cheung TC, Coppieters K, Sanjo H, Oborne LM, Norris PS, Coddington A, Granger SW, Elewaut D, Ware CF.

J Immunol. 2010 Aug 1;185(3):1949-58. doi: 10.4049/jimmunol.1001159. Epub 2010 Jun 30. Erratum in: J Immunol. 2010 Oct 1;185(7):4507.

8.

Decoy receptor 3 is a prognostic factor in renal cell cancer.

Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W.

Neoplasia. 2008 Oct;10(10):1049-56.

9.

Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus.

Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL, Liu LC, Hsu PN.

Clin Exp Immunol. 2008 Mar;151(3):383-90. doi: 10.1111/j.1365-2249.2007.03579.x. Epub 2008 Jan 8.

Supplemental Content

Support Center